Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pharmaniaga Bhd's ROE % for the quarter that ended in Mar. 2026 was 28.00%. Pharmaniaga Bhd's PB Ratio for the quarter that ended in Mar. 2026 was 3.46.
Pharmaniaga Bhd's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was 8.09%.
Pharmaniaga Bhd ROE % Adjusted to Book Value Related Terms
Pharmaniaga Bhd ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for Pharmaniaga Bhd's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharmaniaga Bhd ROE % Adjusted to Book Value Chart
XKLS:7081 vs MCK, CAH, COR: ROE % Adjusted to Book Value Comparison
For the Medical Distribution subindustry, Pharmaniaga Bhd's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharmaniaga Bhd ROE % Adjusted to Book Value vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Pharmaniaga Bhd's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Pharmaniaga Bhd's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of 8.09% mean?
Pharmaniaga Bhd (XKLS:7081) has a ROE % Adjusted to Book Value of 8.09% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Pharmaniaga Bhd and its competitors.
Is Pharmaniaga Bhd's ROE % Adjusted to Book Value too high?
Pharmaniaga Bhd's current ROE % Adjusted to Book Value is 8.09%. Overall, Pharmaniaga Bhd has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Pharmaniaga Bhd's ROE % Adjusted to Book Value compare to MCK and CAH?
Pharmaniaga Bhd's ROE % Adjusted to Book Value of 8.09% can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Medical Distribution company?
A good ROE % Adjusted to Book Value depends on the Medical Distribution industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Pharmaniaga Bhd and its competitors. Pharmaniaga Bhd's current ROE % Adjusted to Book Value is 8.09%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmaniaga Bhd stock overvalued right now?
Based on GuruFocus' analysis, Pharmaniaga Bhd (XKLS:7081) is currently considered Significantly Overvalued. The stock's GF Value™ is RM0.71, compared to a current price of RM1.17 — trading 64.8% above its estimated fair value. The current ROE % Adjusted to Book Value is 8.09%. Pharmaniaga Bhd's overall GF Score™ is 45/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Pharmaniaga Bhd (XKLS:7081), the current ROE % Adjusted to Book Value is 8.09% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharmaniaga Bhd (XKLS:7081) Overvalued in 2026?
Based on GuruFocus' analysis, Pharmaniaga Bhd stock appears to be overvalued.
The current stock price of RM1.17 is trading 64.8% above its estimated GF Value™ of RM0.71.
GuruFocus considers Pharmaniaga Bhd to be Significantly Overvalued.
Key valuation signals for XKLS:7081:
ROE % Adjusted to Book Value: 8.09%
GF Value™: RM0.71 vs. price of RM1.17 (64.8% above fair value)
No single metric tells the full story. See the XKLS:7081 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharmaniaga Bhd is engaged in the manufacture of pharmaceuticals and medical devices. The company is also involved in logistics and distribution. The group operates in three segments - Logistics and distribution, Manufacturing in Malaysia, and Manufacturing and distribution in Indonesia. Maximum revenue is generated by the logistics and distribution segment in Malaysia. The Logistics and distribution segment is engaged in distribution, trading and wholesaling of pharmaceutical and medical products as well as supply and installation of medical and hospital equipment in Malaysia.
45GF Score
Get the complete analysis for XKLS:7081
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:7081 has been successfully added to your 
